WO1999004793A2 - Budipine s'utilisant dans le traitement d'affections inflammatoires du systeme nerveux - Google Patents
Budipine s'utilisant dans le traitement d'affections inflammatoires du systeme nerveux Download PDFInfo
- Publication number
- WO1999004793A2 WO1999004793A2 PCT/EP1998/004457 EP9804457W WO9904793A2 WO 1999004793 A2 WO1999004793 A2 WO 1999004793A2 EP 9804457 W EP9804457 W EP 9804457W WO 9904793 A2 WO9904793 A2 WO 9904793A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- nervous system
- budipin
- acid
- inflammatory diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
Definitions
- the invention relates to the new use of the active ingredient budipin (INN) in the treatment of inflammatory diseases of the nervous system.
- British patent 1313781 describes substituted piperidines which are said to have a long-lasting, centrally stimulating effect.
- One of the active substances covered by the British patent, for which the INN Budipin was later recommended, is used in the treatment of Parkinsonism.
- budipin should be suitable for the treatment of sigma-receptor-modulated diseases.
- budipin inhibits the formation of the tumor necrosis factor ⁇ (TNF- ⁇ ) and interleukin-6 (II-6).
- the invention therefore relates in a first aspect to the use of budipin in the treatment of inflammatory diseases of the nervous system.
- Another object of the invention is the use of budipin in the manufacture of medicaments for the treatment of inflammatory diseases of the nervous system.
- budipin means not only the compound 1-tert-butyl-4,4-diphenylpiperidine, but also its pharmacologically acceptable salts.
- Preferred salts are all pharmacologically acceptable acid addition salts with the inorganic and organic acids commonly used in galenics.
- Suitable as such are water-soluble and water-insoluble acid addition salts with acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2- (4-hydroxybenzoyl) benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, maleic acid Malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, the acids used in salt production - depending on whether it is a mono- or polybasic acid and depending on which salt is desired - be used in an equimolar or a different quantity ratio.
- acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, ace
- TTS transdermal therapeutic system
- auxiliaries and excipients suitable for the desired pharmaceutical formulations on the basis of his specialist knowledge.
- solvents for example antioxidants, dispersants, emulsifiers, defoamers, taste correctives, preservatives, solubilizers, colorants or, in particular, permeation promoters and complexing agents (e.g. cyclodextrins) can be used.
- the active ingredient can be administered orally, rectally, parenterally or percutaneously.
- the pharmaceutical preparations can also contain one or more pharmacologically active constituents of other groups of medicaments.
- the invention further comprises the use of budipin for the treatment of inflammatory diseases of the nervous system. Investigations carried out
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne une nouvelle utilisation du principe actif budipine (INN) dans le traitement d'affections inflammatoires du système nerveux.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU89765/98A AU8976598A (en) | 1997-07-23 | 1998-07-17 | Budipine in the treatment of inflammatory disorders of the nervous system |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1997131521 DE19731521A1 (de) | 1997-07-23 | 1997-07-23 | Budipin bei der Behandlung entzündlicher Erkrankungen des Nervensystems |
| DE19731521.6 | 1997-07-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1999004793A2 true WO1999004793A2 (fr) | 1999-02-04 |
| WO1999004793A3 WO1999004793A3 (fr) | 1999-04-08 |
Family
ID=7836555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1998/004457 WO1999004793A2 (fr) | 1997-07-23 | 1998-07-17 | Budipine s'utilisant dans le traitement d'affections inflammatoires du systeme nerveux |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU8976598A (fr) |
| DE (1) | DE19731521A1 (fr) |
| WO (1) | WO1999004793A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| PT2270052T (pt) | 2001-06-26 | 2018-07-04 | Amgen Fremont Inc | Anticorpos contra opgl |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994369A (en) * | 1995-04-05 | 1999-11-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders |
-
1997
- 1997-07-23 DE DE1997131521 patent/DE19731521A1/de not_active Withdrawn
-
1998
- 1998-07-17 AU AU89765/98A patent/AU8976598A/en not_active Abandoned
- 1998-07-17 WO PCT/EP1998/004457 patent/WO1999004793A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| AU8976598A (en) | 1999-02-16 |
| WO1999004793A3 (fr) | 1999-04-08 |
| DE19731521A1 (de) | 1999-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69737232T2 (de) | Ionische polymere als anti-infektiöse mittel | |
| DE69109286T2 (de) | Pharmazeutische zusammensetzung. | |
| DE10025946A1 (de) | Wirkstoffkombination | |
| WO2001060407A2 (fr) | Nouvelle combinaison d'antihistaminiques non sedatifs et de substances qui influencent l'effet du leucotriene, pour le traitement de la rhinite/conjonctivite | |
| DE69833645T2 (de) | Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen | |
| WO2000037078A1 (fr) | Association de cerivastatine et de fibrates | |
| DE68923151T2 (de) | Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen. | |
| DE3346237A1 (de) | Verwendung von buspiron oder eines pharmazeutisch vertraeglichen saeureadditionssalzes davon zur behandlung extrapyramidaler motorischer stoerungen | |
| DE60030732T2 (de) | Verwendung von 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis | |
| DE69612510T2 (de) | Verwendung von 1-(2-naphtylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode | |
| DE19523502A1 (de) | Kappa-Opiatagonisten für entzündliche Darmerkrankungen | |
| EP1296681A2 (fr) | Utilisation d'inhibiteurs de proteine de transfert de triglycerides microsomale (mtp) pour abaisser les particules de lipoproteine a forte teneur en triglycerides postprandiaux | |
| DE69006707T2 (de) | Verwendung von Fluorochinolon-Derivaten zur Behandlung der Pneumocystis carinii Pneumonie. | |
| DE2359128C2 (fr) | ||
| WO1999004793A2 (fr) | Budipine s'utilisant dans le traitement d'affections inflammatoires du systeme nerveux | |
| WO1996031208A2 (fr) | Utilisation de composes de piperidine ou de pyrrolidine substitues pour le traitement de maladies modulees par un recepteur sigma | |
| DE69522764T2 (de) | Verwendung vom einem Bicycloheptan-Derivat | |
| DE3873210T2 (de) | Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz. | |
| DE60122252T2 (de) | Verfahren zur behandlung von neurodegeneration | |
| EP1001756A1 (fr) | Compositions a effet synergique pour lutter selectivement contre les tissus tumoraux | |
| DE3228351A1 (de) | Arzneimittel zur behandlung von schlafstoerungen | |
| DE60124732T2 (de) | Gatifloxacin als inhibitor der cytokinproduktion | |
| DE19911371A1 (de) | Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen | |
| DE1792271C3 (de) | Blutdrucksenkendes Arzneimittel | |
| DE2720194A1 (de) | Verwendung von trazodon und etoperidon zum behandeln des parkinson-tremors und anderer extra- pyramidaler syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AU BA BG BR CA CN CZ EE GE HR HU ID IL JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AU BA BG BR CA CN CZ EE GE HR HU ID IL JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |